View Pages
Genmab Surges; Banco Sabadell Up After BPCE Stake; Vend Shares Drop
Genmab rallies after epcoritamab+R‑CHOP shows 51% risk reduction in DLBCL; BPCE buys ~7% of Banco Sabadell; Vend plunges after Nordea downgrade citing AI-driven traffic and monetization risks.
Editorial companion
What stands out
The clip highlights a clear clinical win: Genmab and AbbVie reported that epcoritamab plus R‑CHOP cut the risk of disease progression or death by 51% in a phase 3 trial for diffuse large B‑cell lymphoma, a strong topline result that analysts said reduces the risk around future sales estimates. The episode also flags two corporate moves that moved markets: BPCE taking roughly a 7% stake in Banco Sabadell and Nordea downgrading Vend over AI‑related monetization risks, which explains the day’s big winners and losers.
Bullish Gator Snapshot
Current ratings and signals
AbbVie (ABBV)
Bullish
ABBV rates Bullish overall. The fundamental read is neutral: the company passes 7 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.75); revenue is growing about 2.0% per year; net income is declining about 24.0% per year. The technical picture is bullish: price is 23.2% above the 200-day moving average; 8.0% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 72/100), based on 8 news articles from recent coverage.